Awwad et al. [135] found that SLAMF7 was highly expressed by this cell subset in MM patients, and a significant reduction in the percentage of CD8+ Tregs was observed after treatment with the anti-SLAMF7 mAb elotuzumab. The gene discussed is CD8A; the disease is Miyoshi myopathy.